PaTHway Phase 3 Trial Analysis
Overall TEAE Summary
ратнішач
TRIAL
TEAE Summary
Treatment-Emergent Adverse Events (TEAE)
Serious TEAE
TransCon PTH
(N = 61); n (%)
50 (82.0)
5 (8.2)
Placebo
(N = 21); n (%)
21 (100.0)
3 (14.3)
Severity*
Grade ≥3
2 (3.3)
1 (4.8)
Grade 2
21 (34.4)
9 (42.9)
27 (44.3)
11 (52.4)
Grade 1
Related TEAE
30 (49.2)
8 (38.1)
Serious Related TEAE
1 (1.6)
0
TEAE Related to Hyper- or Hypocalcaemia Leading to ER/Urgent
Care Visit and/or Hospitalization
4 (6.6)
2 (9.5)
TEAE Leading to Discontinuation of Study Drug
1 (1.6)**
2 (9.5)
*In the severity categories, patients are displayed for the highest severity category only.
**Death due to cardiac arrest
23 Data on file, Ascendis Pharma 2022.
TransCon PTH is an investigational product candidate.
For investor communication only.
Not for use in product promotion. Not for further distribution.
ascendis
pharmaView entire presentation